Nanohale AG (ETR:FYB)

BRIEF

published on 05/27/2025 at 14:35, 8 months 3 days ago

Formycon and Fresenius Kabi Launch Otulfi™ in Canada

Canadian Market Patient Support Ustekinumab Biosimilar Chronic Autoimmune Diseases Biologic Therapies
PRESS RELEASE

published on 05/27/2025 at 14:30, 8 months 3 days ago

Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
Formycon and Fresenius Kabi announce commercial launch of FYB202/Otulfi ustekinumab biosimilar in Canada, expanding treatment options for chronic autoimmune diseases

Canada Formycon Fresenius Kabi Ustekinumab Biosimilar FYB202/Otulfi
BRIEF

published on 05/19/2025 at 15:05, 8 months 10 days ago

Formycon and Fresenius Kabi Achieve FDA Interchangeability Approval for FYB202/Otulfi®

FDA Approval Biosimilars Formycon Fresenius Kabi Otulfi®
PRESS RELEASE

published on 05/19/2025 at 15:00, 8 months 10 days ago

Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for interchangeability of FYB202/Otulfi (ustekinumab-aauz) with Stelara, enhancing patient access to treatment options for inflammatory diseases in the US

FDA Approval Formycon Fresenius Kabi Biologics Interchangeability
BRIEF

published on 05/12/2025 at 06:35, 8 months 18 days ago

Formycon Achieves Key Milestones in Q1 2025 Amid Challenging Conditions

Strategic Partnerships Financial Guidance Formycon Q1 2025 Biosimilar Approvals FYB202 Launch
PRESS RELEASE

published on 05/12/2025 at 06:30, 8 months 18 days ago

Formycon reports strong operational performance and financial results for first quarter of 2025
Formycon AG reports strong operational performance and financial results for the first quarter of 2025. Market approvals, revenue growth, and strategic partnerships discussed

Financial Results Operational Performance Formycon AG Biosimilars Market Approvals
BRIEF

published on 05/07/2025 at 09:42, 8 months 23 days ago

Formycon Announces Q1 2025 Results Conference and Investor Conferences

Investor Conferences Formycon AG Management Board Financial Outlook Q1 2025 Results
PRESS RELEASE

published on 05/07/2025 at 09:37, 8 months 23 days ago

Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
Formycon AG to discuss Q1 2025 results in a conference call and participate in investor conferences. Details and webcast link available. Biosimilar development focus

Conference Call Investor Conferences Formycon AG Biosimilars Q1 2025 Results
BRIEF

published on 03/27/2025 at 06:35, 10 months 3 days ago

Formycon AG Sees Strong Fiscal Year 2024, Eyes Continued Growth in 2025

Market Position Revenue Forecast Financial Year 2024 Formycon AG Biosimilars
PRESS RELEASE

published on 03/27/2025 at 06:30, 10 months 3 days ago

Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
Formycon reports successful financial year 2024 with strong operational progress and market position enhancement. Key milestones achieved in biosimilar development. Financial outlook for 2025 provided

Market Position Financial Year 2024 Financial Outlook Biosimilar Formycon

Published on 01/30/2026 at 14:00, 42 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 6 hours 7 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 6 hours 42 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 12 hours 27 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 14 hours 42 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 14:11, 30 minutes ago

SBF AG expects stable to positive business development in a challenging environment for 2026
Published on 01/30/2026 at 13:30, 1 hour 11 minutes ago

North Peak Expands Wabash Gold Mineralization at Prospect Mountain, Nevada
Published on 01/30/2026 at 12:00, 2 hours 41 minutes ago

HSBC UK and Sage simplify tax reporting for small businesses ahead of Making Tax Digital
Published on 01/30/2026 at 11:54, 2 hours 48 minutes ago

EQS-Adhoc: YOC AG: PRELIMINARY FIGURES FOR THE 2025 FINANCIAL YEAR
Published on 01/30/2026 at 10:30, 4 hours 12 minutes ago

ASTA ENERGY SOLUTIONS AG SUCCESSFULLY COMPLETES IPO

View all EQS

Published on 01/30/2026 at 08:00, 6 hours 42 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 20 hours 42 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 20 hours 57 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 20 hours 57 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 21 hours 2 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News